Forecast

The analysts' average price target is +2,79€ (+1.062,50%). The median is +2,15€ (+795,83%).

Buy	5
Hold	2
Sell	1

News Go to news feed

Mereo BioPharma licenses alvelestat to Sentynl Therapeutics and secures phase‑3 funding

Mereo BioPharma has entered an option and license agreement with Sentynl Therapeutics (a subsidiary of Zydus Lifesciences) for alvelestat, an oral investigational drug for alpha‑1 antitrypsin deficiency‑associated lung disease. Sentynl can acquire U.S. commercial rights and worldwide manufacturing rights; Mereo retains commercial rights for the rest of the world and will lead the global phase‑3 study and regulatory interactions through study completion. If the option is exercised, Mereo will receive a non‑refundable option fee, up to USD 40 million in up‑front/R&D payments, up to USD 435 million in milestones, and tiered double‑digit percentage royalties on U.S. net sales; a study start in early 2027 is possible. As of 30 June 2026 Mereo held USD 30.1 million in cash and reported a net loss of USD 7.0 million for Q2/2026; the company expects funding to last until the end of 2027 without payments from the Sentynl agreement and also reports ongoing regulatory discussions on setrusumab with Ultragenyx. » More on de.investing.com
Mereo BioPharma stock falls after failed phase-3 trials for Setrusumab

Mereo BioPharma shares plunged about 90% after the phase-3 trials ORBIT and COSMIC for Setrusumab missed their primary endpoints for reducing fracture rates in osteogenesis imperfecta. Secondary endpoints did show significant improvements in bone mineral density but could not prevent investor losses. CEO Dr. Denise Scots-Knight announced further analyses, cost cuts for pre-commercial activities and continued partner talks for other programs such as Alvelestat. Mereo reported a cash balance of $48.7 million as of Q3 2025 and emphasizes strict cost control during the data analysis. » More on de.investing.com
Mereo BioPharma and Ultragenyx continue phase 3 study on osteogenesis imperfecta as planned

Mereo BioPharma and Ultragenyx are proceeding as planned with the phase 3 study of UX143 (setrusumab) for the treatment of osteogenesis imperfecta, after the Data Monitoring Committee confirmed an acceptable safety profile. The final evaluation of the study is expected towards the end of the year, with safety in younger patients consistent with previous findings. Final analyses will be conducted after at least 18 months of patient treatment. » More on de.investing.com

Financials

In the last quarter, Mereo BioPharma (ADR) had revenue of 0.00€ and net profit of −6.14m€

(EUR)	Jun 2026	YoY
Revenue	0.00	100,00%
Gross profit	0.00	100,00%
Net profit	−6.14m	50,50%
EBITDA	−6.12m	49,50%

Fundamentals

Metric	Value
Market capitalization	+37.67m€
Number of shares	159.62m
52-week high/low	+2,03€ - +0,17€
Dividends	No
Beta	0,3
P/E ratio	−1,51
PEG ratio	−0,02
P/B ratio	+1,54
P/S ratio	0,00

Company profile

Mereo BioPharma Group plc, ein biopharmazeutisches Unternehmen, entwickelt und vermarktet Therapeutika für die Behandlung von Onkologie und seltenen Krankheiten im Vereinigten Königreich und international. Sein führender Produktkandidat, Etigilimab (OMP-313M32), ein T-Zell-Antikörper mit Ig- und ITIM-Domänen, befindet sich in der klinischen Phase 1b zur Behandlung von Tumoren. Das Unternehmen entwickelt außerdem Navicixizumab (OMP-305B83), das die klinischen Studien der Phase 1b zur Behandlung von Eierstockkrebs in der Spätphase abgeschlossen hat; Acumapimod (BCT-197), einen p38-MAP-Kinase-Inhibitor, der sich in klinischen Studien der Phase II zur Behandlung akuter Exazerbationen der chronisch obstruktiven Lungenerkrankung befindet; und Leflutrozol (BGS-649), einen oralen Aromatase-Inhibitor zur Behandlung von hypogonadotropem Hypogonadismus. Darüber hinaus entwickelt das Unternehmen Produktkandidaten für seltene Krankheiten, darunter Setrusumab (BPS-804), ein neuartiger Antikörper zur Behandlung von Osteogenesis imperfecta, und Alvelestat (MPH-966), ein oral verabreichtes kleines Molekül, das sich in einer klinischen Phase-II-Studie zur Behandlung des Alpha-1-Antitrypsin-Mangels befindet. Das Unternehmen arbeitet mit dem MD Anderson Cancer Center der University of Texas zusammen, um den therapeutischen Antikörperkandidaten Etigilimab gegen TIGIT zu untersuchen. Die Mereo BioPharma Group plc wurde 2015 gegründet und hat ihren Sitz in London, Vereinigtes Königreich.

Name	Mereo BioPharma (ADR)
CEO	Denise Vera Scots-Knight
Headquarters	London, gl United Kingdom
Website	mereobiopharma.com
Sector	Health Care
Industry	Biotechnology
IPO	04/24/2019
Employees	39